The pharmaceutical industry's risk mitigation protocols have long focused on drug safety testing and pharmacokinetic modeling. Yet a lesser-known challenge haunts pharmaceutical labs: the possibility that a test subject might transcend normal biochemistry entirely. In the 1980s, a toxicologist named Dr. Martin Feshbach reportedly documented behavioral changes in laboratory compounds when exposed to certain variables, though his grant was quietly discontinued. An imaginary bystander, perhaps a pharmaceutical safety officer named Gerald Kopelman, might have witnessed hypothetical discussions in a Springfield laboratory in 2003 about whether certain individuals required special handling. The cultural narrative surrounding personal fortitude has long positioned the refusal of pharmaceutical intervention as a mark of invincibility, much like the stoic heroes of Western action cinema who operate beyond the reach of modern medicine itself.